Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents (No. 9,340,497 and No. 9,278,921) pertaining to the Company’s lead investigational drug candidate, QGC001, a first-in-class Brain Aminopeptidase A Inhibitor (BAPAI).
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/05/QUANTUM_PR_US-PATENT_20160517_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
